{"id":16538,"date":"2021-02-11T08:50:47","date_gmt":"2021-02-11T07:50:47","guid":{"rendered":"https:\/\/idibell.cat\/?p=16538"},"modified":"2021-02-11T08:51:14","modified_gmt":"2021-02-11T07:51:14","slug":"una-debilitat-universal-dels-tumors-solids-obre-la-porta-a-millorar-el-tractament-del-cancer","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/02\/una-debilitat-universal-dels-tumors-solids-obre-la-porta-a-millorar-el-tractament-del-cancer\/","title":{"rendered":"Una debilitat universal dels tumors s\u00f2lids obre la porta a millorar el tractament del c\u00e0ncer"},"content":{"rendered":"<p>Una investigaci\u00f3 liderada per <strong>l\u2019Institut Catal\u00e0 d\u2019Oncologia (<\/strong><a href=\"http:\/\/ico.gencat.cat\/ca\/inici\"><strong>ICO<\/strong><\/a><strong>), Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<\/strong><a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-de-mama\/\"><strong>IDIBELL<\/strong><\/a><strong>), i la Universitat de Calif\u00f2rnia San Francisco (<\/strong><a href=\"https:\/\/www.ucsf.edu\/\"><strong>UCSF<\/strong><\/a><strong>)<\/strong> ha identificat un mecanisme, fins ara desconegut, de regulaci\u00f3 gen\u00e8tica en c\u00e8l\u00b7lules tumorals que ajudaria a predir quins pacients es beneficiarien de la radioter\u00e0pia i quimioter\u00e0pia.<\/p>\n<p>La prote\u00efna TGF\u03b2 \u00e9s un factor de creixement amb implicaci\u00f3 en multitud de processos cel\u00b7lulars essencials. Entre elles posseeix una funci\u00f3 central en la relaci\u00f3 de c\u00e8l\u00b7lules tumorals amb el seu ambient i, en concret, en la inhibici\u00f3 del sistema immunitari que permet la progressi\u00f3 del tumor. Tanmateix, el treball, liderat pels Drs. Mary Helen Barcellos-Hoff (UCSF) i el Dr. Miquel Angel Pujana (ICO i IDIBELL), amb la participaci\u00f3 d\u2019altres investigadors ICO i IDIBELL (Luis Palomero, Roderic Esp\u00edn i \u00c1lvaro Ayt\u00e9s), <strong>descriu una nova propietat de TGF\u03b2 que \u00e9s espec\u00edfica de les c\u00e8l\u00b7lules tumorals i quasi universal a tots els tumors s\u00f2lids<\/strong>.<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-16541 alignleft\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/02\/NP04-MA-Pujana_STM-Imatge-Pujana-300x169.jpg\" alt=\"\" width=\"300\" height=\"169\" srcset=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/02\/NP04-MA-Pujana_STM-Imatge-Pujana-300x169.jpg 300w, https:\/\/idibell.cat\/wp-content\/uploads\/2021\/02\/NP04-MA-Pujana_STM-Imatge-Pujana-1024x576.jpg 1024w, https:\/\/idibell.cat\/wp-content\/uploads\/2021\/02\/NP04-MA-Pujana_STM-Imatge-Pujana-768x432.jpg 768w, https:\/\/idibell.cat\/wp-content\/uploads\/2021\/02\/NP04-MA-Pujana_STM-Imatge-Pujana.jpg 1366w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<blockquote><p>\u201c<em>En conjunt, el treball obre la porta a seleccionar millor els tractaments actuals i, a la vegada, a sensibilitzar certs tumors a la radioter\u00e0pia i quimioter\u00e0pia est\u00e0ndard, millorant la resposta i superviv\u00e8ncia<\/em>.\u201d\u00a0 Dr. Miquel \u00c0ngel Pujana<\/p><\/blockquote>\n<p>&nbsp;<\/p>\n<p>Aquesta nova propietat, identificada gr\u00e0cies a un estudi de Big Data amb milers de pacients, resideix en la capacitat del <strong>TGF\u03b2 en inhibir un proc\u00e9s de reparaci\u00f3 de l\u2019ADN que comporta molts errors<\/strong>. Aix\u00ed, els tumors que tenen actiu TGF\u03b2 poden reparar m\u00e9s fidelment els danys en l\u2019ADN, i per tant, s\u00f3n m\u00e9s resistents a les ter\u00e0pies basades en aquesta lesi\u00f3, com ara la radioter\u00e0pia o algunes quimioter\u00e0pies. Altrament, afirma el Dr. Pujana, a l\u2019inhibir TGF\u03b2 els tumors es sensibilitzarien a aquestes ter\u00e0pies, com per exemple les basades en la inhibici\u00f3 de PARP, aprovades pel tractament de c\u00e0ncer de pr\u00f2stata, mama i ovari.<\/p>\n<p>Els an\u00e0lisis de dades de <strong>superviv\u00e8ncia i resposta al tractament en milers de pacients<\/strong>, incloent-hi diversos tipus de c\u00e0ncers amb molt mal pron\u00f2stic, donen suport a la rellev\u00e0ncia de la relaci\u00f3 entre TGF\u03b2 i la reparaci\u00f3 de l\u2019ADN.<\/p>\n<p>El <strong>Dr. Pujana <\/strong>indica que \u201c<em>en conjunt, el treball obre la porta a seleccionar millor els tractaments actuals i, a la vegada, a sensibilitzar certs tumors a la radioter\u00e0pia i quimioter\u00e0pia est\u00e0ndard, millorant la resposta i superviv\u00e8ncia<\/em>.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019estudi liderat entre l\u2019ICO i l\u2019IDIBELL i la UCSF descriu, gr\u00e0cies a una an\u00e0lisi Big Data, un mecanisme de control de la reparaci\u00f3 de l\u2019ADN que sensibilitzaria els tumors a la ter\u00e0pia.<\/p>\n","protected":false},"author":8,"featured_media":16543,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-13 20:22:52","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/16538"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=16538"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/16538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/16543"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=16538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=16538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=16538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}